In vitro activities of tigecycline against clinical isolates from Shanghai, China

被引:27
作者
Zhang, YY [1 ]
Zhou, L [1 ]
Zhu, DM [1 ]
Wu, PC [1 ]
Hu, FP [1 ]
Wu, WH [1 ]
Wang, F [1 ]
机构
[1] Fudan Univ, Hua Shan Hosp, Inst Antibiot, Shanghai 200433, Peoples R China
关键词
tigecycline; susceptibility testing; antibiotics; minimum inhibitory concentration;
D O I
10.1016/j.diagmicrobio.2004.08.007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To evaluate the in vitro activity of tigecycline, the minimum inhibitory concentrations (MICs) of tigecycline against 1,201 strains of recent clinical isolates from 10 hospitals in Shanghai, China were determined and compared with selected comparators. Results showed that tigecycline had broad-spectrum antimicrobial activity. It was highly active against Gram-positive cocci, including methicillin-resistant Staphylococcus spp., penicillin-intermediate Streptococcus pneumoniae, Enterococcus faecalis and E. faecium. Tigecycline also had good activity against most strains of Enterobacteriaceae, Haemophilus influenzae, Neisseria gonorrhoeae, and Moraxella catarrhalis. However, it was poorly active against Acinetobacter baumannii and Pseudomonas aeruginosa. Tigecycline was highly active against anaerobic Gram-positive cocci such as Peptococcus spp. The in vitro activity of tigecycline was significantly better than that of minocycline and tetracycline. It was as active as or slightly more active than vancomycin and teicoplanin in the activity against resistant aerobic Gram-positive cocci. Tigecycline was bactericidal against all Gram-positive cocci tested except Enterococcus spp. Inoculum size but not pH of medium or concentration of human serum in broth had significant effect on the in vitro activity of tigecycline. Aged media (48-72 hours after preparation) used in the test and specific resistance problem in China may have some effects on MIC values of tigecycline. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:267 / 281
页数:15
相关论文
共 15 条
[1]  
Amsterdam D., 1996, Antibiotics in laboratory medicine, V6th ed.
[2]   Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998 [J].
Babini, GS ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :183-189
[3]   In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain [J].
Betriu, C ;
Rodríguez-Avial, I ;
Sánchez, BA ;
Gómez, M ;
Alvarez, J ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :892-895
[4]   In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases [J].
Biedenbach, DJ ;
Beach, ML ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) :173-177
[5]   In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].
Boucher, HW ;
Wennersten, CB ;
Eliopoulos, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229
[6]  
DAI Z, 1982, ANTIBIOTICS, V7, P288
[7]   Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates [J].
Gales, AC ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :19-36
[8]   Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens [J].
Goldstein, EJC ;
Citron, DM ;
Merriam, CV ;
Warren, Y ;
Tyrrell, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) :2747-2751
[9]   Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci [J].
Hoellman, DB ;
Pankuch, GA ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1085-1088
[10]   EVOLUTION AND SPREAD OF TETRACYCLINE RESISTANCE DETERMINANTS [J].
LEVY, SB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (01) :1-3